Devices that are approved through a process that does not require any clinical evidence for FDA authorization should not ...

The immediate aftermath of the 2024 presidential election has brought renewed attention to regulatory policy at the U.S. Food ...

Medicare drug price negotiation could have significant impacts on investment in post-approval studies for cancer treatment ...

Caremark, Express Scripts, and OptumRx continue to defend themselves against a Federal Trade Commission administrative ...

On September 26, 2024, the White House released an executive order allowing states to use Medicaid to reimburse health care ...

Given the disproportionate impact of climate change on low-income communities of color, Medicaid has an important opportunity to meaningfully invest in communities by mitigating the health impacts of ...

Key policies introduced over the past 45 years have brought new research organizations and investors into the pharmaceutical ...

States can align capitation withholds with value-based payment state-directed payment arrangements to incentivize managed ...

Health Affairs announced today that Editor-in-Chief Alan Weil will leave his role at the end of the year.

In this article, we describe what’s new in Medicare Advantage Organizations' (MAOs’) PY2025 nonmedical benefit offerings and ...

Effective enforcement of the Hospital Price Transparency Rule can empower patients, foster competition, and help control ...

The April 2024 special themed issue of Health Affairs on perinatal mental health and well-being brought together important ...